FRMD6 and glioblastoma: Our results show that expression of TPR-Met fusion protein largely overcomes the FRMD6-mediated anti-GBM effect in vivo (Figure 8C–8D), indicating that FRMD6 exerts its anti-GBM effect at least partially through inhibiting c-Met RTK activity.